LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours

19Sep

LEAP-005 Results at ESMO 2020

Abstract No : Abstract #LBA41

Indication : Gastric Cancer, Colorectal Cancer, Biliary tract cancer, Glioblastoma, Ovarian Cancer, Breast cancer

Intervention : Lenvatinib

Company : Merck & Co.

Technology : multiTKI

Results:

187 pts have been enrolled in LEAP-005. Median study follow-up at Apr 10, 2020 data cutoff was 8.6 (range, 1.9‒13.1) mo. Encouraging efficacy was observed across cohorts, and toxicity was manageable

Conclusion:

Executive Summary

In the interim analysis, prespecified futility efficacy criteria for cohort expansion were met or exceeded, toxicity were manageable in all cohorts. In gastric cancer, ORR: 10%, DCR: 48%. Median PFS: 2.5 months, 6-month rate: 22.2%. Current results show promising efficacy and warrants further randomized trials.